The stock has been in a significant downtrend over the past year, with the price declining 20.69% and underperforming the S&P 500 by 36.62%. The current price of $172.58 is near the lower end of its 52-week range of $165.08 to $234.33, sitting approximately 26% below the high. In the short term, the stock has declined 10.05% over the past month, which is worse than the S&P 500's 5.25% drop. However, over the last three months, it has shown relative strength, declining only 1.70% compared to the S&P 500's 4.63% fall. The price action shows volatility, with a sharp rally in mid-February to over $193 followed by a sell-off to recent lows. The stock is currently trading below its levels from six months ago, indicating persistent bearish pressure despite recent relative outperformance.

Revenue for Q4 2025 was $2.74 billion, representing a 7.47% year-over-year growth from Q4 2024. However, net income for the quarter was $821 million, a significant decline from $1.23 billion in the year-ago quarter, indicating pressure on profitability. The company's financial health is characterized by high leverage, with a debt-to-equity ratio of 12.31. Cash flow remains strong, with operating cash flow of $1.43 billion in Q4 2025 and free cash flow of $848 million, supporting dividends and capital expenditures. Operational efficiency metrics are mixed. The return on equity is exceptionally high at 69.26%, but this is largely driven by the high financial leverage. The current ratio is low at 0.63, indicating potential liquidity constraints relative to short-term obligations.